Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,150,704
  • Shares Outstanding, K 5,558,396
  • Annual Sales, $ 41,908 M
  • Annual Income, $ 9,616 M
  • 60-Month Beta 0.69
  • Price/Sales 4.49
  • Price/Cash Flow 11.79
  • Price/Book 2.87
Trade PFE with:

Options Overview

Details
  • Implied Volatility 23.09%
  • Historical Volatility 10.70%
  • IV Percentile 12%
  • IV Rank 4.95%
  • IV High 110.06% on 03/16/20
  • IV Low 18.56% on 02/12/21
  • Put/Call Vol Ratio 0.40
  • Today's Volume 79,492
  • Volume Avg (30-Day) 131,820
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 1,922,895
  • Open Int (30-Day) 1,900,856

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.86
  • Number of Estimates 6
  • High Estimate 0.96
  • Low Estimate 0.77
  • Prior Year 0.80
  • Growth Rate Est. (year over year) +7.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.36 +0.39%
on 02/26/21
37.04 -9.58%
on 01/27/21
-3.82 (-10.24%)
since 01/26/21
3-Month
33.36 +0.39%
on 02/26/21
43.08 -22.26%
on 12/09/20
-3.04 (-8.32%)
since 11/25/20
52-Week
27.88 +20.12%
on 03/23/20
43.08 -22.26%
on 12/09/20
-1.23 (-3.54%)
since 02/26/20

Most Recent Stories

More News
Varicella Zoster Infection Treatment Market to 2027, Future Outlook, COVID-19 Impact Analysis, Forecast 2021-2027 | Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc. | FMI Report

Future Market Insights (FMI) has published a new report on the titled "Varicella Zoster Infection Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027." Varicella...

ABT : 119.78 (-1.48%)
GSK : 33.61 (-2.24%)
NVS : 85.91 (-0.92%)
PFE : 33.49 (-0.98%)
TEVA : 10.76 (-2.18%)
VRX.TO : 30.80 (-3.33%)
The Latest: First US J&J vaccine doses shipping Sunday night

WASHINGTON — Nearly 4 million doses of the newest COVID-19 vaccine will be shipped Sunday night, and will begin to be delivered to states for injections starting on Tuesday.

PFE : 33.49 (-0.98%)
JNJ : 158.46 (-2.64%)
Germany limits travel from French region over virus variant

BERLIN (AP) — Germany announced Sunday that travelers from France’s northeastern Moselle region will face additional restrictions because of the high rate of variant coronavirus cases there.

PFE : 33.49 (-0.98%)
J&J’s 1-dose shot cleared, giving US 3rd COVID-19 vaccine

WASHINGTON (AP) — The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of two....

JNJ : 158.46 (-2.64%)
PFE : 33.49 (-0.98%)
The Latest: U.S. FDA approves J&J single-shot vaccine

WASHINGTON — The U.S. now has a third vaccine to prevent COVID-19.

PFE : 33.49 (-0.98%)
JNJ : 158.46 (-2.64%)
Asia Today: S. Korea allows workers to squeeze extra doses

SEOUL, South Korea (AP) — South Korea’s Disease Control and Prevention Agency has allowed health workers to squeeze extra doses from vials of coronavirus vaccines developed by AstraZeneca and Pfizer....

PFE : 33.49 (-0.98%)
US advisers endorse single-shot COVID-19 vaccine from J&J

WASHINGTON (AP) — U.S. health advisers endorsed a from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic.

JNJ : 158.46 (-2.64%)
PFE : 33.49 (-0.98%)
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

SNY : 45.89 (+0.20%)
AZN : 48.38 (-1.08%)
PFE : 33.49 (-0.98%)
MRK : 72.62 (-2.68%)
GSK : 33.61 (-2.24%)
BAYRY : 15.3000 (-2.65%)
ABBV : 107.74 (+0.38%)
European Medicines Agency Accepts Pfizer's Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC)...

PFE : 33.49 (-0.98%)
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon,...

PFE : 33.49 (-0.98%)
OPK : 4.50 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

3rd Resistance Point 34.35
2nd Resistance Point 34.12
1st Resistance Point 33.81
Last Price 33.49
1st Support Level 33.27
2nd Support Level 33.04
3rd Support Level 32.73

See More

52-Week High 43.08
Fibonacci 61.8% 37.27
Fibonacci 50% 35.48
Fibonacci 38.2% 33.69
Last Price 33.49
52-Week Low 27.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar